Marc has more than 25 years of biopharma drug discovery and early development expertise spanning multiple therapeutic areas, drug modalities and platform technologies.  He is currently Chief Scientific Officer of Carbon Biosciences, a venture-backed biotech company developing novel gene therapies to overcome the limitations of current delivery technology and reach new patient populations.  Marc’s previous role was SVP, Discovery Research at Dicerna Pharmaceuticals (now a subsidiary of Novo Nordisk) where he led efforts to advance pipeline candidates and develop novel RNAi technologies.  In this role, Marc and his team developed Dicerna’s GalXC-Plus™ RNAi delivery platform, powering multiple corporate partnerships and clinical programs. Earlier, Marc spent over half of his career to-date at Merck and Co., where he led or supported RNAi and small molecule candidates in oncology, virology and immunology.  Marc has a B.S. from Drexel University, M.S. from the University of Rochester and Ph.D. in Biochemistry from Thomas Jefferson University; he has authored over 35 peer-reviewed publications and patents.